# Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis

> **NCT01682512** · PHASE3 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 294 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** BI 695500
- **DRUG:** BI 695500
- **DRUG:** Rituxan®
- **DRUG:** Rituxan®
- **DRUG:** MabThera®

## Key facts

- **NCT ID:** NCT01682512
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09-05
- **Primary completion:** 2015-11-17
- **Final completion:** 2016-10-12
- **Target enrollment:** 294 (ACTUAL)
- **Why stopped:** substance discontinued
- **Last updated:** 2018-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01682512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01682512, "Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01682512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*